Feasibility and Pilot Efficacy Results from the Multi-Site Cognitive Remediation in the Schizophrenia Trials Network ( CRSTN ) Study

@inproceedings{Keefe2010FeasibilityAP,
  title={Feasibility and Pilot Efficacy Results from the Multi-Site Cognitive Remediation in the Schizophrenia Trials Network ( CRSTN ) Study},
  author={Richard Keefe},
  year={2010}
}
Background: Medication non-adherence is a major reason for poor outcomes in schizophrenia. Long-acting injectable (LAI) risperidone microspheres, the first LAI second generation antipsychotic (SGA), may improve adherence and thereby outcomes, but has not been tested in a long-term randomized trial of unstable patients, against flexibly prescribed oral… CONTINUE READING